BIOMAT Database Logo BIOMAT Database Logo

A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis. 1987

B Ljungberg, and M Blombäck, and H Johnsson, and L E Lins

A low molecular heparin fragment (Fragmin, mol. wt. 4-6000 d), given as a single injection (dose 5000 anti-Xa U), was used as an anticoagulant during hemodialysis in 11 patients. In comparison, our routine heparinization procedure was used; conventional heparin was given as a bolus injection at the start and then as continuous infusion during dialysis to prolong the whole blood activated clotting time (WBACT) 125-175%. Fibrin formation, followed by visual inspection and the measuring of fibrinopeptide A and fibrin monomer concentrations were equally suppressed by the two regimens. WBACT was less prolonged with Fragmin. Anti-Xa activity above 0.39 U/ml was maintained throughout the dialyses with Fragmin. In conclusion a single dose of Fragmin gives sufficient anticoagulation for hemodialysis lasting up to 4 hours.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D005260 Female Females
D005337 Fibrin A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot. Antithrombin I
D005344 Fibrinopeptide A Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin. Fibrinopeptides A
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

B Ljungberg, and M Blombäck, and H Johnsson, and L E Lins
[Anticoagulation in hemodialysis with a single dose of low molecular weight heparin].
June 1995, Revista medica de Chile,
B Ljungberg, and M Blombäck, and H Johnsson, and L E Lins
Use of single dose low-molecular-weight heparin in long hemodialysis.
April 1998, The International journal of artificial organs,
B Ljungberg, and M Blombäck, and H Johnsson, and L E Lins
Use of low-dose low molecular weight heparin in hemodialysis.
November 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation,
B Ljungberg, and M Blombäck, and H Johnsson, and L E Lins
Low-molecular-weight heparin for anticoagulation during continuous venovenous hemofiltration.
April 2003, Archives of internal medicine,
B Ljungberg, and M Blombäck, and H Johnsson, and L E Lins
[Use of low-molecular weight heparin during hemodialysis].
January 1997, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,
B Ljungberg, and M Blombäck, and H Johnsson, and L E Lins
Profile of low molecular weight tinzaparin sodium for anticoagulation during hemodialysis.
January 2010, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia,
B Ljungberg, and M Blombäck, and H Johnsson, and L E Lins
Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit.
August 1993, Artificial organs,
B Ljungberg, and M Blombäck, and H Johnsson, and L E Lins
Low-molecular-weight heparin for routine hemodialysis.
October 2008, Hemodialysis international. International Symposium on Home Hemodialysis,
B Ljungberg, and M Blombäck, and H Johnsson, and L E Lins
Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients.
March 1996, Kidney international,
B Ljungberg, and M Blombäck, and H Johnsson, and L E Lins
Safety and efficacy anticoagulation in extracorporeal hemodialysis by simultaneous administration of low-dose prostacyclin and low molecular weight heparin.
January 1998, Minerva medica,
Copied contents to your clipboard!